File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The value of 18F-FDG PET/contrast-enhanced CT in detection of tumor thrombus

TitleThe value of 18F-FDG PET/contrast-enhanced CT in detection of tumor thrombus
Authors
Issue Date2013
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.nuclearmed.com/
Citation
Clinical Nuclear Medicine, 2013, v. 38 n. 2, p. e60-e65 How to Cite?
AbstractPURPOSE: The differentiation between tumor and bland thromboses is important as the management differs. Retrospectively, we aim to evaluate the utility of FDG PET in detecting and differentiating tumor from bland thromboses and if FDG PET provides additional value to contrast-enhanced CT for tumor thrombus detection. PATIENTS AND METHODS: Twenty-four sites of venous thromboembolism, detected on PET/CT, were retrospectively reviewed. Classification of type of thrombosis was based on histology and radiological follow-up. We evaluated the presence of contrast-enhanced CT findings that were suggestive of tumor thrombosis; sign of invasion, neovascularity, and enhancement. Metabolic activity by means of SUV(max) was measured by drawing ROI at the site of thrombosis. Mann-Whitney U test was used to compare the mean SUV(max) between thromboses and internal references. We used ROC analysis to identify the optimal cutoff value of SUV(max) for detection of tumor thrombosis. RESULTS: Twenty-four sites of venous thromboembolism were identified in 15 patients. All tumor thromboses demonstrated at least 1 positive sign on contrast-enhanced CT, whereas 33% of bland thromboses had the same finding. The difference between tumor and bland thrombus SUV(max) was statistically significant (P < 0.005). On ROC analysis, a cutoff of SUV(max) 2.25 (sensitivity, 78%; specificity, 100%) was suggested to differentiate tumor from bland thrombosis. CONCLUSION: PET/CT is able to differentiate tumor from bland thrombosis, with an optimal cutoff value of SUV(max) 2.25. The metabolic information increases the diagnostic accuracy of tumor thrombus and is a useful adjunct to the described features on contrast-enhanced CT.
Persistent Identifierhttp://hdl.handle.net/10722/183717
ISSN
2015 Impact Factor: 4.278
2015 SCImago Journal Rankings: 0.507
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLee, EYPen_US
dc.contributor.authorKhong, PLen_US
dc.date.accessioned2013-06-18T04:09:55Z-
dc.date.available2013-06-18T04:09:55Z-
dc.date.issued2013en_US
dc.identifier.citationClinical Nuclear Medicine, 2013, v. 38 n. 2, p. e60-e65en_US
dc.identifier.issn0363-9762-
dc.identifier.urihttp://hdl.handle.net/10722/183717-
dc.description.abstractPURPOSE: The differentiation between tumor and bland thromboses is important as the management differs. Retrospectively, we aim to evaluate the utility of FDG PET in detecting and differentiating tumor from bland thromboses and if FDG PET provides additional value to contrast-enhanced CT for tumor thrombus detection. PATIENTS AND METHODS: Twenty-four sites of venous thromboembolism, detected on PET/CT, were retrospectively reviewed. Classification of type of thrombosis was based on histology and radiological follow-up. We evaluated the presence of contrast-enhanced CT findings that were suggestive of tumor thrombosis; sign of invasion, neovascularity, and enhancement. Metabolic activity by means of SUV(max) was measured by drawing ROI at the site of thrombosis. Mann-Whitney U test was used to compare the mean SUV(max) between thromboses and internal references. We used ROC analysis to identify the optimal cutoff value of SUV(max) for detection of tumor thrombosis. RESULTS: Twenty-four sites of venous thromboembolism were identified in 15 patients. All tumor thromboses demonstrated at least 1 positive sign on contrast-enhanced CT, whereas 33% of bland thromboses had the same finding. The difference between tumor and bland thrombus SUV(max) was statistically significant (P < 0.005). On ROC analysis, a cutoff of SUV(max) 2.25 (sensitivity, 78%; specificity, 100%) was suggested to differentiate tumor from bland thrombosis. CONCLUSION: PET/CT is able to differentiate tumor from bland thrombosis, with an optimal cutoff value of SUV(max) 2.25. The metabolic information increases the diagnostic accuracy of tumor thrombus and is a useful adjunct to the described features on contrast-enhanced CT.-
dc.languageengen_US
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.nuclearmed.com/-
dc.relation.ispartofClinical Nuclear Medicineen_US
dc.rightsThis is a non-final version of an article published in final form in Clinical Nuclear Medicine, 2013, v. 38 n. 2, p. e60-e65-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subject.meshContrast Media - diagnostic use-
dc.subject.meshFluorodeoxyglucose F18 - diagnostic use-
dc.subject.meshNeoplasms - diagnosis - radiography - radionuclide imaging-
dc.subject.meshPositron-Emission Tomography-
dc.subject.meshThrombosis - diagnosis - radiography - radionuclide imaging-
dc.titleThe value of 18F-FDG PET/contrast-enhanced CT in detection of tumor thrombusen_US
dc.typeArticleen_US
dc.identifier.emailLee, EYP: eyplee77@hku.hken_US
dc.identifier.emailKhong, PL: plkhong@hkucc.hku.hken_US
dc.identifier.authorityLee, EYP=rp01456en_US
dc.identifier.authorityKhong, PL=rp00467en_US
dc.description.naturepostprint-
dc.identifier.doi10.1097/RLU.0b013e318266d53e-
dc.identifier.pmid23334142-
dc.identifier.scopuseid_2-s2.0-84872910500-
dc.identifier.hkuros214902en_US
dc.identifier.hkuros202461-
dc.identifier.volume38en_US
dc.identifier.issue2en_US
dc.identifier.spagee60en_US
dc.identifier.epagee65en_US
dc.identifier.isiWOS:000313798100002-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats